Structure Therapeutics Inc. Income Statement
GPCR / Health Care|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 9.77 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| SG&A Expense | $61.6M | $49.4M | $32.7M | $16.4M |
| R&D Expense | $225.3M | $108.8M | $70.1M | $36.2M |
| Operating Income | -$176.6M | -$158.2M | -$102.8M | -$52.6M |
| Income Tax | $515.0K | $310.0K | $236.0K | $17.0K |
| Net Income | -$141.2M | -$122.5M | -$89.6M | -$51.3M |
| EPS (Basic) | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| EPS (Diluted) | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| Shares Outstanding | 177.6M | 157.9M | 110.2M | 9.6M |